All In Biotech

Drug Trial Radar · NCT05367700

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10382 in Patients With Chronic Myeloid Leukemia.

Last checked: Nov 19, 2026Latest source record: Jan 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

108

Planned (sponsor's estimate)

Start

Apr 28, 2022

Primary completion

Dec 30, 2024

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

Conditions

  • CML, Chronic Phase
  • CML, Accelerated Phase

Interventions

  • HS-10382(Part 1: Dose escalation)Drug

    Single or multiple dose(s) of HS-10382 once daily.

  • HS-10382(Part 2: Dose expansion)Drug

    HS-10382 is administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1(Dose escalation): Maximum tolerated dose (MTD) for HS-10382Time frame: From the single dose to the last dose of the first cycle as 28days of multiple dosing (35days).
  2. Part 2(Dose expansion): Major cytogenetic response (MCyR) rate at 6 monthsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.